Special Drug Use-results Survey for long-term use of Trelief 50mg/day (TOMORROW-PD)
Not Applicable
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000016370
- Lead Sponsor
- Sumitomo Dainippon Pharma Co.,Ltd.
- Brief Summary
As evaluation results on the safety and efficacy of zonisamide in this study were similar to those at the time of pre-approval clinical trial (phase III clinical trial), the safety and efficacy under actual clinical conditions could be confirmed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 566
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had previously received zonisamide, except for cases switching from Trelief 25mg/day treatment to 50mg/day treatment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method